Crohn's disease
Immunology· 4 reviewed drugs· 9591 cited findings behind them
What the regulatory reviews cover
This library contains regulatory review documents for drugs indicated for Crohn's disease. Humira is indicated for inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease. In studies, the Reduction in total EAU group mean scores (both eyes combined) was 76%. Stelara is indicated for moderate to severe Crohn’s disease in adult patients (18 years or older). Clinical Response at Week 6 (Induction Study 3001) was 34.3 %.
It is important to note that these drugs were studied in different trials, and therefore the reported figures are not head-to-head comparisons. Omvoh and Cimzia are also included in this library, but their indications as stated in the review documents do not specifically mention Crohn's disease.
The drugs — one cited result each
| Humira AbbVie Inc. | Reduction in total EAU group mean scores (both eyes combined): 76% ABBVIE INC — Humira FDA Review (NDA/BLA 125057, 2026), p.253 |
| Omvoh Eli Lilly and Company | 2738 cited findings on the drug page → |
| Stelara Johnson & Johnson | Clinical Response at Week 6 (Induction Study 3001): 34.3 % Johnson & Johnson — Stelara FDA Review (BLA761044, ORIG 1, 2, p.113 |
| Cimzia UCB SA | 917 cited findings on the drug page → |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.